

## Original Article

## Development and initial validation of prescribing quality indicators for patients with chronic kidney disease

Kirsten P.J. Smits<sup>1</sup>, Grigory Sidorenkov<sup>1</sup>, Henk J.G. Bilo<sup>2</sup>, Margriet Bouma<sup>3</sup>, Frans J. van Ittersum<sup>4</sup>, Jaco Voorham<sup>1</sup>, Gerjan Navis<sup>5</sup> and Petra Denig<sup>1</sup>

<sup>1</sup>Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, <sup>2</sup>Diabetes Centre, Isala Clinics, Zwolle, The Netherlands, <sup>3</sup>Dutch College of General Practitioners (NHG), Utrecht, The Netherlands, <sup>4</sup>Department of Nephrology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands and <sup>5</sup>Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Correspondence and offprint requests to: Kirsten P.J. Smits. E-mail: k.p.j.smits@umcg.nl

## ABSTRACT

**Background.** Quality assessment is a key element for improving the quality of care. Currently, a comprehensive indicator set for measuring the quality of medication treatment in patients with chronic kidney disease (CKD) is lacking. Our aim was to develop and validate a set of prescribing quality indicators (PQIs) for CKD care, and to test the feasibility of applying this set in practice.

**Methods.** Potential indicators were based on clinical practice guidelines and evaluated using the RAND/UCLA Appropriateness Method. This is a structured process in which an expert panel assesses the validity of the indicators. Feasibility was tested in a Dutch primary care database including >4500 diabetes patients with CKD.

**Results.** An initial list of 22 PQIs was assessed by 12 experts. After changing 10 PQIs, adding 2 and rejecting 8, a final list of 16 indicators was accepted by the expert panel as valid. These PQIs focused on the treatment of hypertension, albuminuria, mineral and bone disorder, statin prescribing and possible unsafe medication. The indicators were successfully applied to measure treatment quality in the primary care database, but for some indicators the number of eligible patients was too small for reliable calculation. Results showed that there was room for improvement in the treatment quality of this population.

**Conclusions.** We developed a set of 16 PQIs for measuring the quality of treatment in CKD patients, which had sufficient content and face validity as well as operational feasibility. These PQIs can be used to point out priority areas for improvement.

**Keywords:** chronic kidney disease, drug therapy, inappropriate prescribing, quality indicators, quality of health care

## INTRODUCTION

People with chronic kidney disease (CKD) have an increased risk of end-stage renal disease [1] as well as cardiovascular morbidity and mortality [2, 3]. These risks can be reduced by appropriate pharmacotherapy, which is stipulated in clinical practice guidelines. These guidelines emphasize adequate treatment of hypertension, albuminuria, anaemia, mineral and bone disorder (MBD) and treatment with statins [4–7]. However, several studies have shown that the provided care is not always in line with these guidelines [8–10] and that the quality of medication treatment in patients with CKD is not optimal [8, 11, 12].

Prescribing quality indicators (PQIs) are used to measure appropriate pharmacotherapy, which includes aspects of medication need, medication choice, safety, adequate dosing, optimal prescribing and adherence [13, 14]. PQIs reflect the proportion of patients that received appropriate (or inappropriate) pharmacotherapy. Quality indicators can be used to monitor, compare or reward providers and provided care and can be part of a quality improvement strategy in audit and feedback programs [15]. Such audit and feedback programs can lead to an increase in the quality of medication treatment by 13% [16].

Internationally, several quality indicator sets regarding CKD care have been developed. The American Renal Physicians Association developed a list of indicators intended to assess

appropriate patient preparation for renal replacement therapy [17]. This set includes nine PQIs focusing on treatment of MBD, hypertension, anaemia and statin prescribing. Litvin and Ornstein [18] developed a set of 12 quality indicators for CKD management in primary care, three of which focused on medication treatment. A Canadian group published a list of 50 criteria that was developed for community pharmacists to assess medication safety issues and adequate medication use by patients with CKD [19]. However, none of these lists covered appropriateness of pharmacotherapy in patients with CKD. Therefore, the goal of this study was to develop a comprehensive set of PQIs for patients with CKD managed in primary or secondary care.

To develop a set of quality indicators, several steps are recommended [20, 21]. First, an initial list of indicators should be generated based on the literature, clinical guidelines and expert consultation. Second, the content and face validity of the indicators should be assessed. Content validity represents whether these indicators correctly reflect the recommendations from clinical guidelines, whereas face validity represents whether a group of experts in the field accept the indicators as measuring quality of care. Next, the operational validity of the indicators should be tested. Operational validity represents the feasibility to calculate the indicators in a reliable way, preferably using routinely collected data [15]. Following these recommendations, our specific aims were to develop a set of PQIs for monitoring CKD care that is both content and face valid and to test the operational validity of the indicators.

## MATERIALS AND METHODS

### Selection of indicators

An initial list of PQIs was developed based on existing national [4, 22–24] and international guidelines [5–7, 25–31] and literature [32–34]. Recommendations with level A or B evidence according to the national guidelines for medication treatment were extracted and converted in potential PQIs by three members of the research team. This first list of potential indicators was discussed with an experienced clinician to refine the indicator definitions. Next, the list was discussed with three patient representatives to ascertain that all relevant topics from the patient perspective were included.

### Content and face validation

To assess the content and face validity of the indicators, the RAND/UCLA Appropriateness Method (RAM) was used [35]. This is a three-round modified Delphi method that combines evidence with expert opinion and consensus and considered an appropriate method for assessing the validity of indicators [36]. Since we intended to assess the face validity of the PQIs for primary and secondary care, an expert panel was formed with four experts from each of three relevant specialties in the Netherlands, namely nephrology, general practice and pharmacy. These were all people with a special interest or expertise with regard to the treatment of CKD patients. Financial compensation was offered to the experts for their time.

During the first round, the experts scored the indicators on three criteria using a 9-point Likert scale. Two of these criteria represent content validity, namely whether the indicator reflected the guidelines adequately ('correct reflection of guidelines') and whether the definitions were correctly formulated ('definitions'). The third criterion, whether following the indicators would result in a health gain for the patient ('health gain'), was included as a general reflection of both content and face validity. The experts received background information, including the guideline recommendations and level of evidence provided in the national guidelines. Levels of evidence were 'A' for evidence from randomized controlled trials and meta-analyses; 'B' for evidence from observational studies, case-control studies and case reports and 'C' for expert opinion. The experts could give comments and propose changes or new indicators during the first round. The second round was a consensus meeting where the experts discussed the discrepancies and were able to change, add and remove indicators. This discussion was chaired by a moderator (P.D.). During the third round, the experts received the adjusted list of indicators, including explanations for the changes, deletions and additions made. This third round was similar to the first round, assessing the criteria 'correct reflection of guidelines' and 'health gain' and one new criterion, i.e. whether the indicator measured a necessary aspect of quality of care ('necessary aspect'), reflecting face validity.

### Operational validity

We tested whether it was feasible to measure the selected PQIs using routinely collected primary care data. Data from the Groningen Initiative to Analyse Type 2 diabetes Treatment (GIANTT) [37] were used. The GIANTT database includes data extracted from medical records of >50 000 patients with type 2 diabetes managed in Dutch primary care. From these, we selected patients with CKD in the year 2012. CKD was defined as having an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m<sup>2</sup> calculated with the chronic kidney disease epidemiology collaboration formula [38]. This corresponds to CKD Stages 3–5 according to the Dutch guidelines [4]. Patients receiving renal replacement therapy were excluded from analysis. The data included information on age, gender, diabetes duration, physical examination, laboratory measurements, comorbidity and prescribed medication. Indicators were considered feasible if all indicator elements could be measured in >2% of patients using the available data. In addition, we calculated the minimum required number of patients for reliable comparison of indicator scores.

The Medical Ethical Committee of the University Medical Center Groningen ascertained that the study does not fall under the Medical Research Involving Human Subjects Act, since it used existing anonymized data.

### Statistical analysis

A PQI was considered content and face valid when (i) all criteria in the third round were rated with a median score  $\geq 7$  and (ii) the criteria were rated without disagreement. As described in the RAM, disagreement among the experts was calculated using the ratio of the Interpercentile Range Adjusted for Symmetry over the Interpercentile Range, where a score of <1 indicates poor agreement [35].

To assess to what extent a PQI can provide reliable scores for performance comparison, we calculated the minimum required number of patients with a moderate precision of 10 percentage points for medication need and medication choice indicators and 5 percentage points for medication safety indicators [39]. These predefined limits were arbitrary, and after observing some indicator scores <5% we decided to conduct the calculations for such indicators using a precision level of 1 percentage point. Based on the absolute numbers, the percentages of eligible patients in our study population and the observed indicator scores, estimates for the total number of patients with CKD needed for reliable indicator scores were calculated (see Supplementary data, File S1).

A sensitivity analysis was conducted to test whether the indicators would yield different results when patients were selected based on two consecutive eGFR measurements. Chi-squared test and where appropriate Fisher's exact test were used to compare indicator outcome scores.

All analyses were conducted using Stata version 13.1 Special Edition (StataCorp, College Station, TX, USA).

## RESULTS

### Face and content validation

**Indicator selection.** An initial list of 22 indicators was selected and defined. Fourteen indicators focused on measuring medication need or medication choice, including three for treatment of hypertension, two for albuminuria, five for MBD, three for anaemia and one for statin prescribing. In addition, eight indicators focused on measuring medication safety and optimal prescribing and one indicator focused on measuring treatment adherence (Table 1). Consultation with the patient representatives did not yield any uncovered topics in our list.

**First round.** An expert panel was formed of four general practitioners, four nephrologists and four pharmacists working in different regions in the Netherlands. In the first round, nine indicators had one criterion and one indicator had two criteria that were scored with uncertainty or disagreement by the experts (Figure 1).

**Second round.** Two pharmacists and one nephrologist were unable to attend the consensus meeting. The moderator voiced their comments during the meeting. Several general changes to the whole list of indicators were agreed upon. It was decided that the indicators should be restricted to patients with CKD Stages 3–5 and to patients  $\leq 80$  years of age except for medication safety indicators.

The indicator measuring medication need for statin prescribing and three of the indicators measuring medication safety scored sufficiently during the first round and remained unchanged. The lower limit of 50 years for the indicator on statin prescribing (Table 1, PQI 4) was debated but accepted since the overall cardiovascular risk in patients <50 years of age without any additional cardiovascular risk factors is often too low to warrant prescribing of statins. Two of the indicators measuring medication need for hypertension, one for albuminuria, three for MBD and four safety

indicators scored insufficiently in the first round and were changed during the consensus meeting (see Table 1). In addition, the selection of patients was adjusted for the indicator on medication need in patients with hypertension. For this indicator, all patients with an indication for treatment, meaning a diagnosis code for hypertension, an elevated level of blood pressure or a prescription for antihypertensives, were considered eligible (Table 1, PQI 1). Furthermore, the experts decided to differentiate two indicators for patients based on their diabetes and albuminuria status (Table 1, PQIs 2A/2B and 3A/3B). For the safety indicators on NSAID prescribing (Table 1, PQIs 11 and 14), the experts decided to include also salicylic acid derivatives when they were prescribed in an oral dose for analgesic, antiphlostatic and/or antipyretic effect (>160 mg/day). Eight indicators were discarded, including one indicator measuring medication need for hypertension, two for MBD treatment, three for anaemia, one measuring medication safety and one measuring treatment adherence (Supplementary data, File S2).

**Third round.** After the consensus meeting, 16 indicators remained, 9 focusing on medication need or medication choice for hypertension, albuminuria, MBD and statin prescribing and 7 focusing on medication safety (Figure 1). These were rated in the third round by all experts. All criteria for these indicators received a median score >7 with sufficient agreement and were therefore included for operational validity testing.

### Operational validity

The indicators were validated in a cohort of 4706 diabetes patients with CKD Stages 3–5 in 2012 (Table 2). Operational definitions could be made for all PQIs using the available data (Supplementary data, File S3). Of the 16 indicators, 10 had a sufficient number of eligible patients for reliable calculation in this large primary care cohort and 4 included <2% of the total population (Table 3). Given the observed proportions and indicator outcomes, the total number of patients with CKD needed for reliable calculation would lie between 490 and 3237 patients for the indicators focusing on medication need and medication choice for hypertension, albuminuria and statin prescribing. For the medication safety indicators, a source population of 327–3241 patients with CKD would be sufficient for reliable calculation. Reliable calculation of the scores of the MBD indicators and the safety indicators on vitamin D, digoxin and NSAID prescribing was not possible due to limited availability of phosphate and calcium levels, the low prevalence of phosphate binders, vitamin D and digoxin prescriptions and the low prevalence of patients CKD Stages 4–5 in our population.

Indicator outcome scores for medication need and medication choice ranged from 59% for prescribing the recommended combination of an angiotensin-converting enzyme (ACE)-inhibitor/angiotensin II receptor blocker (ARB) and a diuretic in patients with CKD, diabetes and micro-albuminuria to 93% for prescribing antihypertensive medication in patients with CKD and hypertension. For the indicators on medication safety, the results ranged from 0.3% for prescribing an erythropoiesis-stimulating agent (ESA) in patients with normal haemoglobin (Hb) levels to 21% for prescribing metformin in patients with an eGFR < 30 mL/min/1.73 m<sup>2</sup> (Table 3).

**Table 1. Indicators with changes made during evaluation process by experts**

Final indicator description; ( <i>x</i> ) in <i>italic</i> are indicators not included in final set of 16 PQIs	Changes made during evaluation process
<i>Treatment of hypertension</i>	
1. The percentage of patients between the ages of 18 and 80 years with CKD Stages 4–5 and hypertension who are prescribed antihypertensives (evidence level: A) unless undesirable because of low diastolic blood pressure (added by expert panel)	<ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– CKD stage restricted to Stages 4 and 5</li> <li>– Restriction of low diastolic blood pressure added</li> </ul>
(I) <i>The percentage of patients with CKD Stages 3–5 with a prescription of antihypertensives who are prescribed an ACE inhibitor or ARB (evidence level: B)</i>	Removed
2a. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 and macro-albuminuria treated with multiple antihypertensives who are prescribed a combination of an ACE inhibitor or ARB and a diuretic (evidence level: B)	<ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– No gender-specific albuminuria cut-off level</li> <li>– Restricted to macro-albuminuria</li> </ul>
2b. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5, micro-albuminuria and diabetes treated with multiple antihypertensives who are prescribed a combination of an ACE inhibitor or ARB and a diuretic (evidence level: B)	Added <ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– No gender-specific albuminuria cut-off level</li> <li>– Restricted to micro-albuminuria and diabetes</li> </ul>
<i>Treatment of albuminuria</i>	
3a. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 and macro-albuminuria who are prescribed an ACE inhibitor or an ARB (evidence level: A)	<ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– No gender-specific albuminuria cut-off level</li> <li>– Restricted to macro-albuminuria</li> </ul>
3b. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5, micro-albuminuria and diabetes who are prescribed an ACE inhibitor or an ARB (evidence level: A)	Added <ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– No gender-specific albuminuria cut-off level</li> <li>– Restricted to micro-albuminuria and diabetes</li> </ul>
<i>Prescription of statins</i>	
4. The percentage of patients between the ages of 50 and 65 years with CKD Stages 3–5 who are prescribed a statin (evidence level B for patients with high cardiovascular risk)	No changes
<i>Treatment of MBD</i>	
5. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 and an elevated phosphate level who are prescribed a phosphate binder (evidence level: B for control of phosphate level)	<ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– Aluminium hydroxide added as phosphate binders</li> <li>– For calcium-containing phosphate binders, a minimal dose of &gt;1× daily is required</li> </ul>
(II) <i>The percentage of patients with CKD Stages 3–5 without increased phosphate who start with a phosphate binder (evidence level: B)</i>	Removed
6. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 treated with phosphate binders and with an elevated calcium level who are prescribed a non-calcium-containing phosphate binder (evidence level: B for control of calcium level)	<ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– Aluminium hydroxide added as phosphate binders</li> <li>– A correction of calcium levels for albumin is required</li> </ul>
7. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 treated with phosphate binders and with a low calcium level who are prescribed a calcium-containing phosphate binder (evidence level: B for control of calcium level)	<ul style="list-style-type: none"> <li>– Age restricted between 18 and 80 years</li> <li>– Aluminium hydroxide added as phosphate binders</li> <li>– A correction of calcium levels for albumin is required</li> </ul>
(III) <i>The percentage of patients with CKD Stages 3–5 with elevated PTH levels who are prescribed vitamin D (evidence level: B)</i>	Removed
<i>Treatment of anaemia</i>	
(IV) <i>The percentage of patients with CKD Stages 3–5 with iron deficiency anaemia who are prescribed iron supplements (evidence level: A for control of serum haemoglobin level)</i>	Removed
(V) <i>The percentage of patients with CKD Stages 3–5, anaemia and adequate iron supplementation who are prescribed ESA (evidence level: A for control of serum haemoglobin level)</i>	Removed
(VI) <i>The percentage of patients with CKD Stages 3–5 without low Hb or Hct level who start with iron supplements (evidence level: B)</i>	Removed
<i>Medication safety</i>	
8. The percentage of patients ≥18 years of age with CKD Stages 3–5 and a prescription of RAS blockers who are prescribed at least two RAS blockers simultaneously (evidence level: A)	No changes
9. The percentage of patients ≥18 years of age with CKD Stages 3–5 and elevated calcium levels who are prescribed active vitamin D (evidence level: B for control of calcium level)	<ul style="list-style-type: none"> <li>– Vitamin D restricted to active vitamin D</li> </ul>

Continued

**Table 1. Continued**

Final indicator description; ( <i>x</i> ) in <i>italic</i> are indicators not included in final set of 16 PQIs	Changes made during evaluation process
10. The percentage of patients ≥18 years of age with CKD Stages 3–5 and Hb ≥7.5 who are prescribed ESA (evidence level: B)	No changes
11. The percentage of patients ≥18 years of age with eGFR <30 mL/min/1.73 m <sup>2</sup> who are prescribed an NSAID (evidence level: B)	– NSAID including salicylic acid derivatives (carbasalate calcium) when used for analgesic, antiphlostatic and/or antipyretic effect (>160 mg/day)
12. The percentage of patients ≥18 years of age with eGFR <30 mL/min/1.73 m <sup>2</sup> and diabetes who are prescribed metformin (evidence level: B)	– Restricted to diabetes
13. The percentage of patients ≥18 years of age with eGFR <50 mL/min/1.73 m <sup>2</sup> who are prescribed digoxin >0.125 mg/day (evidence level: B)	– No changes
14. The percentage of patients ≥18 years of age with CKD Stages 3–5 and who are prescribed with a combination of NSAID, RAS blocker and diuretic (evidence level: B)	– Restricted to Stages 3 and 5 – NSAID including salicylic acid derivatives (carbasalate calcium) when used for analgesic, antiphlostatic and/or antipyretic effect (>160 mg/day)
(VII) <i>The percentage of patients with CKD and who are prescribed an RAS inhibitor and potassium-sparing diuretic simultaneously whose potassium levels are measured (evidence level: B)</i>	Removed
<i>Treatment adherence</i>	
(VIII) <i>The percentage of patients with CKD and who are prescribed an ACE inhibitor/ARB and a diuretic who are prescribed a combination pill (no evidence level)</i>	Removed

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; Hct, haematocrit; NSAID, non-steroidal anti-inflammatory drug, including salicylic acid and derivatives; PTH, parathyroid hormone; RAS, renin-angiotensin system. Evidence levels: A, randomized controlled trials and/or meta-analyses; B, observational studies, case-control studies and/or case reports; C, expert opinion.

The sensitivity analysis did not yield different results except for the indicator on medication need for statins. Statin prescribing was higher in patients with confirmed CKD (two consecutive eGFR measurements <60 mL/min/1.73 m<sup>2</sup>) compared with patients with unconfirmed CKD (79.5 and 67.5%, respectively, P = 0.009).

## DISCUSSION

We developed a set of 16 PQIs, which is intended for measuring the quality of pharmacotherapy in patients with CKD Stages 3–5. The indicators are derived from evidence-based guideline recommendations and were approved by experts in the Netherlands. The PQIs focus on medication need and medication choice for the treatment of hypertension, albuminuria, MBD and statin prescribing, as well as on medication safety. Most of the indicators could be operationalized using routinely collected data from a primary care database. The number of eligible patients needed for reliable estimates was >1250 for 11 of the indicators. To our knowledge, this is the first validated set of indicators for measuring prescribing quality in patients with CKD.

Our indicator set covers the domains medication need and medication choice for four therapeutic areas relevant for CKD patients (nine indicators), as well as the domains medication safety and optimal prescribing (seven indicators on unsafe combinations, contraindications and dosing). In contrast, previously developed indicator sets for CKD focused mainly on adequate monitoring of risk factors for CKD progression and not on medication treatment [18]. One medication indicator included in several general quality indicator sets measures ACE inhibitor/ARB treatment in patients with albuminuria [40, 41]. This indicator is also included in our PQIs set.

Medication safety was extensively covered by the pharmacotherapy assessment in chronic renal disease (PAIR) criteria developed by Desrochers *et al.* [19]. However, these criteria are intended for evaluation of individual patient's treatment and have not been converted to quality indicators.

Using a medical records database that includes routinely collected data about physical examination, laboratory measurement, comorbidity and prescribed medication, we were able to make operational definitions for all indicators. To identify patients eligible for treatment, different approaches can be used [42]. In the development phase, the experts decided to apply a combination of diagnosis codes, clinical measurements and prescribed medication to identify patients having hypertension. Such an approach was deemed necessary since diagnosis coding in medical records is seldom complete [42–44] and a difference in quality of diagnosis registration between health care providers can influence the indicator scores. Also, to identify all the patients in need of a phosphate binder, both clinical measurements and prescribed medication were used. Including clinical measurements is expected to increase the sensitivity of identification of poorly treated patients [42], whereas including patients with prescribed medication is expected to increase the sensitivity of identification of well-treated patients. It is possible, however, that these medications were prescribed for other indications, reducing the specificity of the indicators and leading to overestimating their outcome.

The quality of pharmacotherapy in primary care diabetes patients with CKD was found to be suboptimal, with indicator scores <80% for prescribing ACE inhibitors/ARBs, statins and phosphate binders when needed and >10% for potentially unsafe prescribing of vitamin D, metformin and digoxin. PQIs are also used to compare healthcare providers. With an estimated prevalence of 4% of CKD patients in primary care [45], most of




FIGURE 1: Evaluation process of the indicators during the RAND/UCLA rounds.

**Table 2. Patient characteristics at baseline**

Variable	Number of patients with observation (%)	Mean ± standard deviation
Age (years)	4706 (100)	77.1 ± 8.7
Male gender	1859 (39.5)	
<b>Measurements</b>		
eGFR (ml/min/1.73m <sup>2</sup> )	4706 (100)	47.1 (10.3)
<b>CKD stage</b>		
Stage 3	4335 (92.1)	50.5 (43.5–55.8) <sup>a</sup>
Stage 4	343 (7.3)	25.5 (22.0–27.8) <sup>a</sup>
Stage 5	28 (0.6)	11.9 (7.8–13.6) <sup>a</sup>
Systolic blood pressure (mmHg)	4580 (97.3)	141.5 (19.6)
High systolic blood pressure (>140 mmHg)	2090 (44.4)	154 (148–165) <sup>a</sup>
Diastolic blood pressure (mmHg)	4580 (97.3)	75.1 (10.4)
Low diastolic blood pressure (<70 mmHg)	1178 (25.0)	63 (60–66) <sup>a</sup>
Albumin/creatinine ratio (mg/mmol)	3409 (72.4)	1.4 (0.0–4.9) <sup>a</sup>
Microalbuminuria (3–30 mg/mmol)	884 (18.8)	7.2 (4.5–12.8) <sup>a</sup>
Macroalbuminuria (>30 mg/mmol)	235 (5.0)	70.4 (42.1–121.7) <sup>a</sup>
Phosphate (mmol/L)	156 (3.3)	1.0 (0.2)
High phosphate level (>1.49 mmol/L)	6 (0.1)	1.6 (0.1)
Calcium (mmol/L)	290 (6.2)	2.4 (0.2)
High calcium level (>2.54 mmol/L)	17 (0.4)	2.6 (2.6–2.7) <sup>a</sup>
Hb (mmol/L)	2264 (48.1)	8.1 (1.0)
Low Hb level (<7.5 mmol/L)	602 (12.8)	7.0 (6.6–7.3)
<b>Medication</b>		
Antihypertensives	4075 (86.6)	
Diuretics	2904 (61.7)	
Beta-blocking agents	2474 (52.6)	
Calcium channel blockers	1341 (28.5)	
Agents acting on the RAS	3184 (67.7)	
ACE inhibitors	1937 (41.2)	
ARBs	1360 (28.9)	
Other agents acting on the RAS	13 (0.3)	
Statins	2858 (60.7)	
Phosphate binders	70 (1.5)	
Calcium-containing phosphate binders	65 (1.4)	
Non-calcium-containing phosphate binders	6 (0.1)	
Vitamin D	132 (2.8)	
ESA	30 (0.6)	
NSAIDs	438 (9.3)	
Metformin	2411 (51.2)	
Digoxin	220 (4.7)	

<sup>a</sup>Median with interquartile range.

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; NSAID, non-steroidal anti-inflammatory drug, including salicylic acid and derivatives; RAS, renin-angiotensin system.

these indicators should not be used to compare scores of individual general practitioners. Moreover, the indicators focusing on treatment of MBD and unsafe vitamin D prescribing may not be relevant for primary care, since <2% of patients from the source population were eligible. These indicators may be more relevant for a secondary care population [17].

Of note, the level of evidence supporting some indicators is higher than for others. In patients with CKD, multiple (cardiovascular and renal) outcomes need to be considered. In addition, many large trials do not exclusively include patients with CKD. For these reasons, we included indicators based on evidence from randomized clinical trials or meta-analysis (level A) and from observational studies, case-control studies and case reports (level B). When assessing the indicators, the expert panel sometimes decided to adapt the definitions of an indicator, based on their knowledge and experience, to make them more useful for practice. For example, indicator 2b was defined during the consensus meeting to differentiate between patients with and without diabetes. As such, the indicators provide insight into prescribing for CKD patients at the level of a healthcare provider or organization but should not be seen as an evidence-based assessment of appropriate care at the individual patient level. Also, the focus of our indicators is the prescribing behaviour of a healthcare provider and not the actual use of drugs by patients. This is particularly relevant for indicators that include drugs, such as NSAIDs, that are available over the counter. The PQIs are not intended to signal inappropriate use of such drugs. Furthermore, several of the safety indicators include a large group of CKD patients in the denominator, only excluding patients in whom such drug prescribing is considered safe. As a consequence, the indicator outcome can be close to 0% and appear non-informative. In such cases, the numerator may be more informative, providing the absolute number of patients who may be exposed to medication that should be avoided.

Several strengths and limitations should be considered. First, as is the case with any consensus method, the results may depend on the selected panel. Our expert panel consisted of 12 experts from three relevant disciplines, namely nephrology, general practice and pharmacy, equally represented. Our intention was to reach consensus across these disciplines on indicators intended for primary and secondary care. From general practice, we invited professionals who either contributed to the transmural guideline for the treatment of CKD or who conducted scientific research or training related to this topic. The total number of participants satisfies the requirement according to the RAM to include 7–15 experts to the panel [35]. Using more experts may impede the consensus meeting, which is an important round for making essential changes to the indicators. Per discipline, however, the number of experts was limited. Two pharmacists and one nephrologist could not attend the consensus meeting but their comments and suggestions were voiced by the moderator. All indicators were discussed, allowing for consensus, as well as indicators receiving sufficient scores in the first round. In the third round, all experts assessed the final list of indicators. Second, the indicators were based on recommendations from national evidence-based guidelines for clinical practice [4, 22–24]. The recommendations in these Dutch guidelines are similar to those in other international guidelines, such as proposed by the European Renal Best Practice, the Kidney Disease Improving Global Outcomes and Kidney Disease Outcomes Quality Initiative guidelines [5–7, 25–31]. This makes our indicators useful for other countries. The PQIs, however, should be updated when guidelines are updated. Third, we

**Table 3. Assessments in final round of RAND/UCLA method and outcomes from operational validity testing of indicators**

Indicator	Final scores			Operational validity				
	Correct reflection guidelines?	Health gain for patient?	Necessary to measure?	Outcome score (%) in study cohort	Numerator/denominator (eligible) in study cohort	Percentage of eligible patients in total cohort (n = 4706)	Eligible patients needed for comparison	Minimal number of CKD patients needed for reliable comparison
<b>Treatment of hypertension</b>								
1. The percentage of patients between the ages of 18 and 80 years with CKD Stages 4–5 and hypertension who are prescribed antihypertensives unless undesirable because of low diastolic blood pressure	8.5	8	8	92.9	92/99	2.1	≥26	1238
2a. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 and macro-albuminuria treated with multiple antihypertensives who are prescribed a combination of an ACE inhibitor or ARB and a diuretic	8.5	8	8	60.5	81/134	2.8	≥92	3237
2b. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5, micro-albuminuria and diabetes treated with multiple antihypertensives who are prescribed a combination of an ACE inhibitor or ARB and a diuretic	8.5	8	8	58.9	321/545	11.6	≥93	805
<b>Treatment of albuminuria</b>								
3a. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 and macro-albuminuria who are prescribed an ACE inhibitor or an ARB	9	9	9	81.9	122/149	3.2	≥57	1804
3b. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5, micro-albuminuria and diabetes who are prescribed an ACE inhibitor or an ARB	8.5	8.5	8.5	78.0	495/635	13.5	≥66	490
<b>Prescription of statins</b>								
4. The percentage of patients between the ages of 50 and 65 years with CKD Stages 3–5 who are prescribed a statin	9	8.5	9	74.3	271/365	7.7	≥74	956
<b>Treatment of MBD</b>								
5. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 and an elevated phosphate level who are prescribed a phosphate binder	9	8.5	8.5	75.0	39/52	1.1	≥73	6619
6. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 treated with phosphate binders and with an elevated calcium level who are prescribed a non-calcium-containing phosphate binder	9	8.5	8.5	—	0/0	0.0	≥96	— <sup>a</sup>
7. The percentage of patients between the ages 18 and 80 years with CKD Stages 3–5 treated with phosphate binders and with a low calcium level who are prescribed a calcium-containing phosphate binder	8.5	7.5	8	—	1/1	0.0	≥96	— <sup>a</sup>

Continued

Table 3. Continued

Indicator	Final scores			Operational validity				
	Correct reflection guidelines?	Health gain for patient?	Necessary to measure?	Outcome score (%) in study cohort	Numerator/denominator (eligible) in study cohort	Percentage of eligible patients in total cohort (n = 4706)	Eligible patients needed for comparison	Minimal number of CKD patients needed for reliable comparison
<b>Medication safety</b>								
8. The percentage of patients ≥18 years with CKD Stages 3–5 and a prescription of RAS blockers who are prescribed at least two RAS blockers simultaneously	8.5	9	9	3.7	117/3193	67.7	≥1369 <sup>b</sup>	2022
9. The percentage of patients ≥18 years with CKD Stages 3–5 and elevated calcium levels who are prescribed active vitamin D	9	8.5	8	17.7	3/17	0.4	≥224	— <sup>a</sup>
10. The percentage of patients ≥18 years with CKD Stages 3–5 and Hb ≥7.5 who are prescribed an ESA	9	9	9	0.3	5/1662	35.2	≥115 <sup>b</sup>	327
11. The percentage of patients ≥18 years with eGFR <30 mL/min/1.73 m <sup>2</sup> who are prescribed an NSAID	9	9	9	3.0	11/371	7.9	≥1118 <sup>b</sup>	14 209
12. The percentage of patients ≥18 years with eGFR <30 mL/min/1.73 m <sup>2</sup> and diabetes who are prescribed metformin	9	8	8	21.0	78/371	7.9	≥255	3241
13. The percentage of patients ≥18 years with eGFR <50 mL/min/1.73 m <sup>2</sup> who are prescribed digoxin >0.125 mg/day	9	8.5	8	11.1	16/144	3.1	≥152	4977
14. The percentage of patients ≥18 years with CKD Stages 3–5 and who are prescribed with a combination of NSAID, RAS blocker and diuretic	9	9	9	4.6	216/4706	99.8	≥1686 <sup>b</sup>	1690

<sup>a</sup>Not estimated due to low number of eligible patients in this cohort.

<sup>b</sup>Eligible patients calculated using a precision of 1 percentage point due to low outcome of indicator.

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; NSAID, non-steroidal anti-inflammatory drug, including salicylic acid and derivatives; RAS, renin-angiotensin system.

used a single eGFR measurement to define the CKD stage. Using two measurements gives more precision in classifying the CKD stage, thereby decreasing false selection of patients for the indicators [46]. Our sensitivity analysis showed that similar outcomes were obtained for all but one indicator. Finally, we tested the operational validity of the indicators in a primary care cohort, while some of the indicators, especially those measuring medication need for MBD, may be more relevant for secondary care.

In conclusion, a set of 16 PQIs for CKD Stage 3–5 patients was developed and validated using the RAM method. The indicators focus on medication need and medication choice for hypertension, albuminuria, MBD, statin prescribing and medication safety. The indicators can be used to point out priority areas for improvement. Due to the small number of patients with CKD Stages 3–5 in a primary care practice, these indicators cannot be used for benchmarking of individual healthcare providers in primary care. At the practice level, the indicators can be used for evaluation and for giving feedback to healthcare providers on the quality of prescribing. The safety indicators

might also be used by healthcare providers in an alerting system. Further validation of the PQIs usefulness in a secondary care cohort is needed.

#### SUPPLEMENTARY DATA

Supplementary data are available online at <http://ndt.oxfordjournals.org>.

#### ACKNOWLEDGEMENTS

We would like to thank the experts that participated in our panel: Drs J.A.M. van Balen, Dutch College of General Practitioners; Dr W.J.W. Bos, St. Antonius Hospital; Dr Y. Groeneveld, retired general practitioner; Dr P.J. Helmons, St. Jansdal Hospital; Dr M.H. Hemmelder, Medical Center Leeuwarden; Prof. dr H.A.H. Kaasjager, University Medical Center Utrecht; Prof. dr J.G.W. Kosterink, University Medical

Center Groningen; Prof. dr C. Neef, Maastricht University Medical Center; Dr F.J. van den Oever, St. Fransiscus Hospital; Dr N. Scherpbier-de Haan, Radboud University Medical Center; Dr W. Verstappen, Radboud University Medical Center.

This study has been funded by ZonMW—the Netherlands Organisation for Health Research and Development.

## CONFLICT OF INTEREST STATEMENT

None declared.

## REFERENCES

1. Gansevoort RT, Matsushita K, van der Velde M *et al.* Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int* 2011; 80: 93–104
2. Matsushita K, van der Velde M, Astor BC *et al.* Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010; 375: 2073–2081
3. Go AS, Chertow GM, Fan D *et al.* Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; 351: 1296–1305
4. De Grauw WJC, Kaasjager HAH, Bilo HJG *et al.* Landelijk Transmurale Afspraak Chronische nierschade [Dutch Transmural Agreement Chronic Kidney Disease]. *Huisarts Wet* 2009; 52: 586–597
5. Bilo H, Coenstra L, Couchoud C *et al.* Clinical practice guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). *Nephrol Dial Transplant* 2015; 30(Suppl 2): ii1–142
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 2013; 3: 1–150
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39(2 Suppl 1): S1–266
8. Allen AS, Forman JP, Orav EJ *et al.* Primary care management of chronic kidney disease. *J Gen Intern Med* 2011; 26: 386–392
9. van Zuilen AD, Blankestijn PJ, van Buren M *et al.* Quality of care in patients with chronic kidney disease is determined by hospital specific factors. *Nephrol Dial Transplant* 2010; 25: 3647–3654
10. Eilat-Tsanani S, Reitman A, Dayan M *et al.* Management of kidney disease in patients with diabetes in the primary care setting. *Prim Care Diabetes* 2014; 8: 159–163
11. Litvin CB, Nietert PJ, Wessell AM *et al.* Recognition and management of CKD in primary care. *Am J Kidney Dis* 2011; 57: 646–647
12. Stadler SL, Bhardwaj B, Olson KL *et al.* An assessment of cholesterol goal attainment in patients with chronic kidney disease. *J Clin Lipidol* 2010; 4: 298–304
13. Martirosyan L, Voorham J, Haaijer-Ruskamp FM *et al.* A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. *Pharmacoepidemiol Drug Saf* 2010; 19: 319–334
14. Dreischulte T, Grant AM, McCowan C *et al.* Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. *BMC Clin Pharmacol* 2012; 12: 5
15. Campbell SM, Braspenning J, Hutchinson A *et al.* Research methods used in developing and applying quality indicators in primary care. *Qual Saf Health Care* 2002; 11: 358–364
16. Ivers N, Jamtvedt G, Flottorp S *et al.* Audit and feedback: effects on professional practice and healthcare outcomes. *Cochrane Database Syst Rev* 2012; 6: CD000259
17. Bolton WK. Renal physicians association clinical practice guideline: appropriate patient preparation for renal replacement therapy: guideline number 3. *J Am Soc Nephrol* 2003; 14: 1406–1410
18. Litvin CB, Ornstein SM. Quality indicators for primary care: an example for chronic kidney disease. *J Ambul Care Manage* 2014; 37: 171–178
19. Desrochers JF, Lemieux JP, Morin-Belanger C *et al.* Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD. *Am J Kidney Dis* 2011; 58: 527–535
20. Campbell SM, Kontopantelis E, Hannon K *et al.* Framework and indicator testing protocol for developing and piloting quality indicators for the UK quality and outcomes framework. *BMC Fam Pract* 2011; 12: 85
21. Kotter T, Blozik E, Scherer M. Methods for the guideline-based development of quality indicators—a systematic review. *Implement Sci* 2012; 7: 21
22. Rensma PL, Hagen EC, Van Bommel EFH *et al.* Richtlijn voor de behandeling van patienten met Chronische Nierschade (CNS) [Dutch Treatment Guideline for patients with Chronic Kidney Disease]. 2009
23. Rutten GEHM, De Grauw WJC, Nijpels G *et al.* NHG-Standard Diabetes mellitus type 2 (derde herziening) [The Dutch College of General Practitioners—Practice Guideline Diabetes mellitus type 2 (third revision)]. *Huisarts Wet* 2013; 56: 512–525
24. Nederlands Huisartsen Genootschap (NHG) [The Dutch College of General Practitioners]. Cardiovasculair risicomanagement (Tweede herziening) [Dutch Guideline Cardiovascular Risk Management (Second revision)]. *Huisarts Wet* 2012; 55: 14–28
25. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney Int Suppl* 2012; 2: 279–335
26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int* 2009; 76(Suppl 113): S1–S130
27. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl* 2012; 2: 337–414
28. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guidelines for lipid management in chronic kidney disease. *Kidney Int Suppl* 2013; 3: 259–305
29. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 2003; 42(4 Suppl 3): S1–201
30. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis* 2004; 43(5 Suppl 1): S1–290
31. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. *Am J Kidney Dis* 2012; 60: 850–886
32. Makani H, Bangalore S, Desouza KA *et al.* Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. *BMJ* 2013; 346: f360
33. Susantitaphong P, Sewaralthab K, Balk EM *et al.* Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. *Am J Hypertens* 2013; 26: 424–441
34. Lapi F, Azoulay L, Yin H *et al.* Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. *BMJ* 2013; 346: e8525
35. Fitch K, Bernstein SJ, Aguilar MD *et al.* The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA: RAND, 2001
36. Naylor CD. What is appropriate care? *N Engl J Med* 1998; 338: 1918–1920
37. Voorham J, Denig P. Computerized extraction of information on the quality of diabetes care from free text in electronic patient records of general practitioners. *J Am Med Inform Assoc* 2007; 14: 349–354
38. Levey AS, Stevens LA, Schmid CH *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150: 604–612

39. van Doorn-Klomberg AL, Braspenning JC, Feskens RC *et al.* Precision of individual and composite performance scores: the ideal number of indicators in an indicator set. *Med Care* 2013; 51: 115–121
40. Shekelle PG, MacLean CH, Morton SC *et al.* ACOVE quality indicators. *Ann Intern Med* 2001; 135(8 Pt 2): 653–667
41. National Institute for Health and Care Excellence (NICE). Quality Outcomes Framework (QOF). <http://www.nice.org.uk/standards-and-indicators/qofindicators>
42. Martirosyan L, Arah OA, Haaijer-Ruskamp FM *et al.* Methods to identify the target population: implications for prescribing quality indicators. *BMC Health Serv Res* 2010; 10: 137
43. Botsis T, Bassoe CF, Hartvigsen G. Sixteen years of ICPC use in Norwegian primary care: looking through the facts. *BMC Med Inform Decision Making* 2010; 10: 11
44. Herrett E, Shah AD, Boggon R *et al.* Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. *BMJ* 2013; 346: f2350
45. van Gelder VA, Scherpier-de Haan ND, de Grauw WJ *et al.* Impact on cardiovascular risk follow-up from a shift to the CKD-EPI formula for eGFR reporting: a cross-sectional population-based primary care study. *BMJ Open* 2013; 3: e003631
46. Li L, Astor BC, Lewis J *et al.* Longitudinal progression trajectory of GFR among patients with CKD. *Am J Kidney Dis* 2012; 59: 504–512

*Received for publication: 8.7.2015; Accepted in revised form: 16.11.2015*